Cargando…

Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome

OBJECTIVES: This study was performed to investigate the changes and influencing factors of liver controlled attenuation parameter (CAP) in obese patients with polycystic ovary syndrome (PCOS), and to determine the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) in PCOS patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dongxu, Nan, Nan, Bing, Hao, He, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501797/
https://www.ncbi.nlm.nih.gov/pubmed/37720537
http://dx.doi.org/10.3389/fendo.2023.1241734
_version_ 1785106187112415232
author Wang, Dongxu
Nan, Nan
Bing, Hao
He, Bing
author_facet Wang, Dongxu
Nan, Nan
Bing, Hao
He, Bing
author_sort Wang, Dongxu
collection PubMed
description OBJECTIVES: This study was performed to investigate the changes and influencing factors of liver controlled attenuation parameter (CAP) in obese patients with polycystic ovary syndrome (PCOS), and to determine the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) in PCOS patients with obesity. METHODS: Forty-one PCOS patients with obesity and twenty age- and body mass index (BMI)-matched control women without PCOS were enrolled in this study. General data, body composition, biochemical parameters, sex hormones, and liver CAP in the two groups were collected and compared. Liver CAP was measured using transient elastography. RESULTS: NAFLD was more common in the Obese PCOS group than in the control group (75.61% vs. 45.00%, P=0.018). Compared to the control group, the obese PCOS group showed apparent increases in alanine transaminase (ALT), aspartate transaminase (AST), CAP, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), totle testosterone (TT), free androgen index (FAI), fasting insulin (FIns), and homeostasis model assessment-insulin resistance (HOMA-IR), along with lower high-density lipoprotein cholesterol (HDL-C) and sex hormone binding globulin (SHBG) levels. In addition, as shown by Spearman analysis, liver CAP in PCOS patients with obesity had a positive correlation with ALT, AST, TG, TT, FAI, FIns, and HOMA-IR, and a negative correlation with SHBG. Logistic regression analysis showed that TG, TT, FIns, and HOMA-IR were risk factors for NAFLD, while TT was an independent risk factor for NAFLD in PCOS patients with obesity. CONCLUSION: PCOS patients with obesity had a significantly higher prevalence of NAFLD. Furthermore, in PCOS patients with obesity, liver CAP was associated with disorders of lipid metabolism, insulin resistance, and hyperandrogenemia, with elevated testosterone levels being an independent risk factor for NAFLD in PCOS patients with obesity.
format Online
Article
Text
id pubmed-10501797
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105017972023-09-15 Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome Wang, Dongxu Nan, Nan Bing, Hao He, Bing Front Endocrinol (Lausanne) Endocrinology OBJECTIVES: This study was performed to investigate the changes and influencing factors of liver controlled attenuation parameter (CAP) in obese patients with polycystic ovary syndrome (PCOS), and to determine the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) in PCOS patients with obesity. METHODS: Forty-one PCOS patients with obesity and twenty age- and body mass index (BMI)-matched control women without PCOS were enrolled in this study. General data, body composition, biochemical parameters, sex hormones, and liver CAP in the two groups were collected and compared. Liver CAP was measured using transient elastography. RESULTS: NAFLD was more common in the Obese PCOS group than in the control group (75.61% vs. 45.00%, P=0.018). Compared to the control group, the obese PCOS group showed apparent increases in alanine transaminase (ALT), aspartate transaminase (AST), CAP, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), totle testosterone (TT), free androgen index (FAI), fasting insulin (FIns), and homeostasis model assessment-insulin resistance (HOMA-IR), along with lower high-density lipoprotein cholesterol (HDL-C) and sex hormone binding globulin (SHBG) levels. In addition, as shown by Spearman analysis, liver CAP in PCOS patients with obesity had a positive correlation with ALT, AST, TG, TT, FAI, FIns, and HOMA-IR, and a negative correlation with SHBG. Logistic regression analysis showed that TG, TT, FIns, and HOMA-IR were risk factors for NAFLD, while TT was an independent risk factor for NAFLD in PCOS patients with obesity. CONCLUSION: PCOS patients with obesity had a significantly higher prevalence of NAFLD. Furthermore, in PCOS patients with obesity, liver CAP was associated with disorders of lipid metabolism, insulin resistance, and hyperandrogenemia, with elevated testosterone levels being an independent risk factor for NAFLD in PCOS patients with obesity. Frontiers Media S.A. 2023-08-31 /pmc/articles/PMC10501797/ /pubmed/37720537 http://dx.doi.org/10.3389/fendo.2023.1241734 Text en Copyright © 2023 Wang, Nan, Bing and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wang, Dongxu
Nan, Nan
Bing, Hao
He, Bing
Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
title Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
title_full Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
title_fullStr Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
title_full_unstemmed Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
title_short Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
title_sort controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501797/
https://www.ncbi.nlm.nih.gov/pubmed/37720537
http://dx.doi.org/10.3389/fendo.2023.1241734
work_keys_str_mv AT wangdongxu controlledattenuationparameterstoassessliversteatosisinobesepatientswithpolycysticovarysyndrome
AT nannan controlledattenuationparameterstoassessliversteatosisinobesepatientswithpolycysticovarysyndrome
AT binghao controlledattenuationparameterstoassessliversteatosisinobesepatientswithpolycysticovarysyndrome
AT hebing controlledattenuationparameterstoassessliversteatosisinobesepatientswithpolycysticovarysyndrome